{"id":"darunavir-ritonavir-truvada","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Diarrhea"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"variable","effect":"Elevated lipids"},{"rate":"1-5","effect":"Renal impairment (Truvada component)"}]},"_chembl":{"chemblId":"CHEMBL1201127","moleculeType":"Small molecule","molecularWeight":"593.74"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darunavir is a protease inhibitor that blocks HIV protease, preventing the maturation of viral particles. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing darunavir levels. Truvada (tenofovir/emtricitabine) are nucleoside reverse transcriptase inhibitors that block viral reverse transcriptase. Together, they suppress HIV replication through multiple mechanisms.","oneSentence":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:05.721Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"},{"name":"HIV-1 prevention (pre-exposure prophylaxis with Truvada component)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT02275780","phase":"PHASE3","title":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-12-01","conditions":"HIV-1","enrollment":769},{"nctId":"NCT02486133","phase":"PHASE3","title":"Dual Therapy With Boosted Darunavir + Dolutegravir","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-07","conditions":"HIV-Infection","enrollment":269},{"nctId":"NCT02336074","phase":"PHASE2","title":"Research In Viral Eradication of HIV Reservoirs","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-11-27","conditions":"HIV","enrollment":60},{"nctId":"NCT02269917","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-03","conditions":"Human Immunodeficiency Virus Type 1","enrollment":1149},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT01869634","phase":"PHASE4","title":"Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2013-06","conditions":"Human Immunodeficiency Virus Infection","enrollment":37},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT01348763","phase":"PHASE1","title":"The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-10","conditions":"HIV","enrollment":13},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01367236","phase":"PHASE4","title":"Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"HIV, Impaired Cognition","enrollment":60},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02770508","phase":"PHASE4","title":"Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2015-11","conditions":"HIV-1 Infection","enrollment":145},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT00928187","phase":"PHASE3","title":"Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-11","conditions":"HIV, HIV Infections","enrollment":454},{"nctId":"NCT02159599","phase":"PHASE4","title":"Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2014-07","conditions":"HIV Infection","enrollment":249},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01363011","phase":"PHASE3","title":"Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-05","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":106},{"nctId":"NCT01345630","phase":"PHASE3","title":"Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2011-09","conditions":"HIV-1","enrollment":813},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334},{"nctId":"NCT00757783","phase":"PHASE4","title":"Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2008-10","conditions":"HIV","enrollment":68},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT00534352","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2008-01","conditions":"HIV-1 Infection","enrollment":23},{"nctId":"NCT01294761","phase":"NA","title":"Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir","status":"COMPLETED","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2011-02","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT01118871","phase":"PHASE4","title":"The First Failure Study","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2010-05","conditions":"HIV, HIV Infections","enrollment":3},{"nctId":"NCT00525733","phase":"NA","title":"Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2007-10","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01258439","phase":"PHASE4","title":"Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.","status":"COMPLETED","sponsor":"St Vincent's Hospital, Sydney","startDate":"2010-11","conditions":"HIV, Cardiovascular Disease","enrollment":25},{"nctId":"NCT02203461","phase":"PHASE1","title":"Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2014-07","conditions":"Insulin Resistance","enrollment":30},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00677300","phase":"PHASE4","title":"Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients","status":"COMPLETED","sponsor":"Dallas VA Medical Center","startDate":"2009-01","conditions":"HIV Infections","enrollment":85},{"nctId":"NCT00811954","phase":"PHASE3","title":"Comparative Study of Three NNRTI-Sparing HAART Regimens","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-05","conditions":"HIV Infection","enrollment":1814},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT02097381","phase":"NA","title":"Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2010-04","conditions":"HIV Infection","enrollment":10},{"nctId":"NCT01033760","phase":"PHASE3","title":"Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2010-04","conditions":"HIV-1 Infections","enrollment":90},{"nctId":"NCT00827112","phase":"PHASE2","title":"A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-03","conditions":"Human Immunodeficiency Virus-1","enrollment":129},{"nctId":"NCT01343225","phase":"PHASE4","title":"Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection","status":"UNKNOWN","sponsor":"East Carolina University","startDate":"2011-05","conditions":"HIV","enrollment":40},{"nctId":"NCT01066065","phase":"","title":"Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients","status":"UNKNOWN","sponsor":"Hospital Carlos III, Madrid","startDate":"2010-02","conditions":"Cardiovascular Disease, HIV Infections","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prezista","Norvir","Truvada"],"phase":"marketed","status":"active","brandName":"Darunavir, Ritonavir, Truvada","genericName":"Darunavir, Ritonavir, Truvada","companyName":"Imperial College London","companyId":"imperial-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 prevention (pre-exposure prophylaxis with Truvada component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}